Daiichi Sankyo launches the antiplatelet agent Efient® 3.75mg/5mg tablets
Posted: 27 May 2014 | | No comments yet
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® 3.75mg/5mg Tablets in Japan…
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched the antiplatelet agent Efient® 3.75mg/5mg Tablets in Japan (JAN: Prasugrel Hydrochloride; approval to market: March 24, 2014; NHI drug price listing: May 23, 2014).
Efient® is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited. The results of phase 3 clinical trials in Japanese patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI) demonstrated that Efient® reduces the incidence of ischemic events from the perioperative period of PCI by rapidly reducing platelet aggregation activity.
Through the launch of the Efient® treatment option in Japan, Daiichi Sankyo aims to benefit patients and healthcare professionals by providing a new approach to therapy for ischemic heart disease.
Based on co-development of the agent outside of Japan by Daiichi Sankyo and Eli Lilly and Company, the European Commission and the US FDA granted marketing authorization for Efient®/Effient® for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing PCI, in combination with aspirin, in 2009. To date, prasugrel has been approved in more than 70 countries worldwide.
